• Positive depression results from XanaCIDD phase 2a trial
• Pivotal XanaMIA phase 2b/3 AD clinical trial passes 100th participant milestone
• Appointed experienced inaugural Chief Commercial Officer (CCO) to manage commercialization activities

Actinogen Medical Ltd (ASX: ACW) has announced its financial results for the year ended 30 June 2025. The company reported a net loss after tax of $14.7 million, with revenue from ordinary activities increasing by 135% to $685,253. Highlights for the year include positive depression results from the XanaCIDD phase 2a trial, which showed clinically and statistically significant benefits on depression symptoms with Xanamem 10 mg once daily. The pivotal XanaMIA phase 2b/3 Alzheimer's disease clinical trial also passed the 100th participant milestone, with an interim analysis scheduled for January 2026 and final results expected in Q4 2026. Actinogen also appointed an experienced inaugural Chief Commercial Officer, Andy Udell, based in the USA to manage commercialization activities. The company completed an $11.1 million capital raise, received a $9.0 million R&D tax incentive rebate, and established a $13.8 million non-dilutive R&D tax incentive funding facility to secure funding through mid-late 2026.

The company is focused on advancing its lead compound, Xanamem, through pivotal trials for Alzheimer's disease and major depressive disorder. The positive results from the XanaCIDD depression trial and progress on the XanaMIA Alzheimer's trial are key milestones as Actinogen prepares for potential commercialization of Xanamem.